NCT03631316View on ClinicalTrials.gov

Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir

NACompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

October 30, 2018

Study Completion Date

November 1, 2018

Conditions
Kidney TransplantationCytomegalovirus InfectionsPharmacokineticsTherapeutic Equivalency
Interventions
DRUG

Generic Valganciclovir

900 mg daily during 4 days

DRUG

Innovative Valganciclovir

900 mg daily during 4 days

Trial Locations (1)

14080

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City

All Listed Sponsors
lead

Luis Eduardo Morales Buenrostro

OTHER

NCT03631316 - Pharmacokinetic Parameters of Innovative Valganciclovir Versus Generic Valganciclovir | Biotech Hunter | Biotech Hunter